Rare Cannabinoid Focus InMed Pharmaceuticals is a leader in the development and commercialization of rare cannabinoids, presenting sales opportunities for pharmaceutical and health and wellness markets due to the increasing interest in cannabinoid-based products.

Expansion of Therapeutics Pipeline With the advancement of therapies targeting neurodegenerative diseases and preclinical data on promising pharmacological effects for dry age-related macular degeneration, InMed is expanding its therapeutic pipeline, providing potential sales avenues in these specific disease areas.

High-profile Scientific Advisory Board The appointment of renowned experts like Dr. Barry Greenberg and Dr. David G. Morgan to InMed's Scientific Advisory Board enhances credibility and opens doors for collaborations, partnerships, and potential sales opportunities through their expertise and networks.

Upcoming Funding Infusion InMed Pharmaceuticals is planning to receive significant funding, creating opportunities for business development professionals to engage in strategic partnerships, scale operations, and invest in innovative sales and marketing initiatives to drive revenue growth.

Participation in Key Events InMed's active participation in events like the Emerging Growth Conference signifies a proactive approach to industry engagement, providing platforms for networking, showcasing products, and nurturing leads that can translate into potential sales deals and partnerships.